SCHEMBL30734231

SCHEMBL30734231

Nc1cc(-c2ccc3ncnc(N4CCN(c5ccncc5)CC4)c3c2)ccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 16/20 0.52
CYP1A2 P05177 14/20 0.52
CLK4 Q9HAZ1 14/20 0.52
ALDH1A1 P00352 11/20 0.52
CYP2D6 P10635 10/20 0.52
LMNA P02545 9/20 0.52
MAPK1 P28482 9/20 0.52
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
ALOX15 P16050 1/20 0.52
HIF1A Q16665 10/20 0.51
USP2 O75604 8/20 0.50
MAP4K4 O95819 1/20 0.50
KDM4E B2RXH2 2/20 0.49
HSD17B10 Q99714 3/20 0.47
CYP2C19 P33261 7/20 0.47
IRAK4 Q9NWZ3 1/20 0.46
TSHR P16473 5/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30734187 0.91 ACHE (0.53) CYP3A4CYP1A2CLK4ALDH1A1CYP2D6
SCHEMBL30734233 0.89 ACHE (0.55) CYP3A4CYP1A2CLK4ALDH1A1CYP2D6
SCHEMBL30734232 0.89 ALDH1A1 (0.49) CYP3A4CYP1A2CLK4ALDH1A1CYP2D6
SCHEMBL30734171 0.87 CYP1A2 (0.62) CYP3A4CYP1A2CLK4ALDH1A1CYP2D6
SCHEMBL30734206 0.86 CYP3A4 (0.50) CYP3A4CYP1A2CLK4ALDH1A1CYP2D6
SCHEMBL30734169 0.85 CYP3A4 (0.54) CYP3A4CYP1A2CLK4ALDH1A1CYP2D6
SCHEMBL30734203 0.82 ACHE (0.56) CYP3A4CYP1A2CLK4ALDH1A1CYP2D6
SCHEMBL31745229 0.81 CYP1A2 (0.52) CYP3A4CYP1A2CLK4ALDH1A1CYP2D6
SCHEMBL31745183 0.81 MEN1 (0.54) CYP3A4CYP1A2CLK4ALDH1A1CYP2D6
SCHEMBL30734129 0.81 ACHE (0.55) CYP3A4CYP1A2CLK4ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF UNIV ARIZONA (US) 2025-12-18 US disclosed
EP-4543888-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF Arizona Board of Regents on behalf of The University of Arizona (US) 2025-04-30 EP disclosed
WO-2023250083-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2023-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK3, CLK1 CYP3A4 3677/4885CYP1A2 3648/4885CLK4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.